Gastric Cancer in the Era of Precision Medicine

Cellular and Molecular Gastroenterology and Hepatology

Volumn 3, Issue 3, 2017, Pages 348-358

  Liu, Xi ^a,b   Meltzer, Stephen J ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer Genomics; Gastric Cancer; Molecular Classification; Preclinical Models

Indexed keywords

PEMBROLIZUMAB; RAMUCIRUMAB; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; ENVIRONMENTAL FACTOR; EPIGENETICS; HOST; HUMAN; MICROSATELLITE INSTABILITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATIC MUTATION; STOMACH CANCER; STOMACH CARCINOGENESIS;

EID: 85018350546     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2017.02.003     Document Type: Review

References (137)

1. 1 Fitzmaurice, C., Dicker, D., Pain, A., et al. The global burden of cancer 2013. JAMA Oncol 1 (2015), 505–527.
2. 2 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
3. 3 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
4. 4 Anderson, W.F., Camargo, M.C., Fraumeni, J.F., et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303 (2010), 1723–1728.
5. 5 Lauren, P., The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64 (1965), 31–49.
6. 6 Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
7. 7 Fuchs, C.S., Tomasek, J., Yong, C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
8. 8 The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
9. 9 Cristescu, R., Lee, J., Nebozhyn, M., et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21 (2015), 449–456.
10. 10 Li, X., Wu, W.K., Xing, R., et al. Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability. Cancer Res 76 (2016), 1724–1732.
11. 11 Song, J.H., Meltzer, S.J., MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143 (2012), 35–47 e2.
12. 12 Fang, X.Y., Pan, H.F., Leng, R.X., et al. Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett 356 (2015), 357–366.
13. 13 McCracken, K.W., Catá, E.M., Crawford, C.M., et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516 (2014), 400–404.
14. 14 Sachs, N., Clevers, H., Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 24 (2014), 68–73.
15. 15 Merker, S.R., Weitz, J., Stange, D.E., Gastrointestinal organoids: how they gut it out. Dev Biol 420 (2016), 239–250.
16. 16 Hidalgo, M., Amant, F., Biankin, A.V., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4 (2014), 998–1013.
17. 17 McCracken, K.W., Aihara, E., Martin, B., et al. Wnt/β-catenin promotes gastric fundus specification in mice and humans. Nature 541 (2017), 182–187.
18. 18 Correa, P., Houghton, J., Carcinogenesis of Helicobacter pylori. Gastroenterology 133 (2007), 659–672.
19. 19 Correa, P., Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19 (1995), S37–S43.
20. 20 Bouvard, V., Baan, R., Straif, K., et al. A review of human carcinogens: part B—biological agents. Lancet Oncol 10 (2009), 321–322.
21. 21 Moss, S.F., The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Mol Gastroenterol Hepatol 3 (2017), 183–191.
22. 22 Plummer, M., Franceschi, S., Vignat, J., et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 136 (2015), 487–490.
23. 23 Hatakeyama, M., Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 15 (2014), 306–316.
24. 24 Wadhwa, R., Song, S., Lee, J.S., et al. Gastric cancer: molecular and clinical dimensions. Nat Rev Clin Oncol 10 (2013), 643–655.
25. 25 Graham, D.Y., Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148 (2015), 719–731.e3.
26. 26 Hamilton, J.P., Meltzer, S.J., A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol 4 (2006), 416–425.
27. 27 Chow, W.H., Blaser, M.J., Blot, W.J., et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58 (1998), 588–590.
28. 28 Chen, J.N., He, D., Tang, F., et al. Epstein-Barr virus-associated gastric carcinoma: a newly defined entity. J Clin Gastroenterol 46 (2012), 262–271.
29. 29 Hino, R., Uozaki, H., Murakami, N., et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69 (2009), 2766–2774.
30. 30 Shinozaki-Ushiku, A., Kunita, A., Fukayama, M., Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol 46 (2015), 1421–1434.
31. 31 Oliveira, C., Pinheiro, H., Figueiredo, J., et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 16 (2015), e60–e70.
32. 32 Hansford, S., Kaurah, P., Li-Chang, H., et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1 (2015), 23–32.
33. 33 Worthley, D., Phillips, K., Wayte, N., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61 (2012), 774–779.
34. 34 McLean, M.H., El-Omar, E.M., Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 11 (2014), 664–674.
35. 35 Kakiuchi, M., Nishizawa, T., Ueda, H., et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 46 (2014), 583–587.
36. 36 Wong, S.S., Kim, K.M., Ting, J.C., et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun, 5, 2014, 5477.
37. 37 Chen, K., Yang, D., Li, X., et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A 112 (2015), 1107–1112.
38. 38 Geddert, H., Zur Hausen, A., Gabbert, H.E., et al. EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst) 33 (2010), 143–149.
39. 39 Yu, H., Jove, R., The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 4 (2004), 97–105.
40. 40 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
41. 41 Lane, D.P., Cancer: p53, guardian of the genome. Nature 358 (1992), 15–16.
42. 42 Zang, Z.J., Cutcutache, I., Poon, S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44 (2012), 570–574.
43. 43 Wang, K., Kan, J., Yuen, S.T., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43 (2011), 1219–1223.
44. 44 Wang, K., Yuen, S.T., Xu, J., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46 (2014), 573–582.
45. 45 Lin, Y., Wu, Z., Guo, W., et al. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol 36 (2015), 7385–7394.
46. 46 Ott, K., Vogelsang, H., Mueller, J., et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9 (2003), 2307–2315.
47. 47 Kim, K.M., Kwon, M.S., Hong, S.J., et al. Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Arch 443 (2003), 491–500.
48. 48 Wu, M.S., Chang, M.C., Huang, S.P., et al. Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer. Genes Chromosomes Cancer 30 (2001), 80–86.
49. 49 Arakawa, N., Sugai, T., Habano, W., et al. Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers. Mol Carcinog 56 (2017), 527–537.
50. 50 Weiss, M.M., Kuipers, E.J., Postma, C., et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 26 (2004), 307–317.
51. 51 Deng, N., Goh, L.K., Wang, H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61 (2012), 673–684.
52. 52 Muro, K., Chung, H.C., Shankaran, V., et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17 (2016), 717–726.
53. 53 Chia, N.-Y., Deng, N., Das, K., et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut 64 (2015), 707–719.
54. 54 Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Med 16 (2010), 793–798.
55. 55 Tao, J., Deng, N.T., Ramnarayanan, K., et al. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med, 3, 2011, 77ra30.
56. 56 Lee, J., Lee, S.E., Kang, S.Y., et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119 (2013), 1627–1635.
57. 57 Yao, F., Kausalya, J.P., Sia, Y.Y., et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep 12 (2015), 272–285.
58. 58 Hause, R.J., Pritchard, C.C., Shendure, J., et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22 (2016), 1342–1350.
59. 59 Kim, T.M., Park, P.J., A genome-wide view of microsatellite instability: old stories of cancer mutations revisited with new sequencing technologies. Cancer Res 74 (2014), 6377–6382.
60. 60 Mori, Y., Yin, J., Rashid, A., et al. Instabilotyping comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res 61 (2001), 6046–6049.
61. 61 Rhyu, M.G., Park, W.S., Meltzer, S.J., Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 9 (1994), 29–32.
62. 62 Yoon, K., Lee, S., Han, T.S., et al. Comprehensive genome- and transcriptome-wide analyses of mutations associated with microsatellite instability in Korean gastric cancers. Genome Res 23 (2013), 1109–1117.
63. 63 David, S., Meltzer, S.J., Stomach-genetic and epigenetic alterations of preneoplastic and neoplastic lesions. Cancer Biomark 9 (2011), 493–507.
64. 64 Yamamoto, H., Perez-Piteira, J., Yoshida, T., et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 116 (1999), 1348–1357.
65. 65 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
66. 66 Sato, F., Meltzer, S.J., CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106 (2006), 483–493.
67. 67 Toyota, M., Ahuja, N., Suzuki, H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59 (1999), 5438–5442.
68. 68 Zouridis, H., Deng, N., Ivanova, T., et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med, 4, 2012 156ra140.
69. 69 Qu, Y., Dang, S., Hou, P., Gene methylation in gastric cancer. Clin Chim Acta 424 (2013), 53–65.
70. 70 Ando, T., Yoshida, T., Enomoto, S., et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 124 (2009), 2367–2374.
71. 71 Ueda, T., Volinia, S., Okumura, H., et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11 (2010), 136–146.
72. 72 Tsai, K.W., Wu, C.W., Hu, L.Y., et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 129 (2011), 2600–2610.
73. 73 Liu, Z., Zhang, J., Gao, Y., et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. Clin Cancer Res 20 (2014), 4598–4612.
74. 74 Kim, J.G., Takeshima, H., Niwa, T., et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett 330 (2013), 33–40.
75. 75 Sepulveda, J.L., Gutierrez-Pajares, J.L., Luna, A., et al. High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. Mod Pathol 29 (2016), 182–193.
76. 76 Niwa, T., Tsukamoto, T., Toyoda, T., et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 70 (2010), 1430–1440.
77. 77 Matsusaka, K., Kaneda, A., Nagae, G., et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 71 (2011), 7187–7197.
78. 78 Liang, Q., Yao, X., Tang, S., et al. Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer. Gastroenterology 147 (2014), 1350–1362. e4.
79. 79 Gigek, C.O., Chen, E.S., Calcagno, D.Q., et al. Epigenetic mechanisms in gastric cancer. Epigenomics 4 (2012), 279–294.
80. 80 Chi, P., Allis, C.D., Wang, G.G., Covalent histone modifications: miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10 (2010), 457–469.
81. 81 Lee, S., Kim, J., Kim, W., et al. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28 (2009), 184–194.
82. 82 Zhang, L., Zhong, K., Dai, Y., et al. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients. J Gastroenterol 44 (2009), 305–312.
83. 83 Muratani, M., Deng, N., Ooi, W.F., et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nat Commun, 5, 2014, 4361.
84. 84 Park, Y.S., Jin, M.Y., Kim, Y.J., et al. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15 (2008), 1968–1976.
85. 85 Petrocca, F., Visone, R., Onelli, M.R., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13 (2008), 272–286.
86. 86 Zhang, Z., Li, Z., Gao, C., et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88 (2008), 1358–1366.
87. 87 Zhang, B.G., Li, J.F., Yu, B.Q., et al. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 27 (2012), 1019–1026.
88. 88 Katada, T., Ishiguro, H., Kuwabara, Y., et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 34 (2009), 537–542.
89. 89 Han, T.S., Hur, K., Xu, G., et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut 64 (2015), 203–214.
90. 90 Ding, L., Xu, Y., Zhang, W., et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20 (2010), 784–793.
91. 91 Zheng, B., Liang, L., Wang, C., et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17 (2011), 7574–7583.
92. 92 Wu, S., Liu, F., Xie, L., et al. miR-125b suppresses proliferation and invasion by targeting MCL1 in gastric cancer. Biomed Res Int, 2015, 2015, 365273.
93. 93 Zhang, X., Peng, Y., Jin, Z., et al. Integrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinoma. Oncotarget 6 (2015), 32878–32889.
94. 94 Xu, Z.Y., Yu, Q.M., Du, Y.A., et al. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci 9 (2013), 587–597.
95. 95 Li, H., Yu, B., Li, J., et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5 (2014), 2318–2329.
96. 96 Yang, F., Bi, J., Xue, X., et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J 279 (2012), 3159–3165.
97. 97 Zhang, E.B., Kong, R., Yin, D.D., et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5 (2014), 2276–2292.
98. 98 Sun, M., Jin, F.Y., Xia, R., et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer, 14, 2014, 319.
99. 99 Sun, M., Xia, R., Jin, F., et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35 (2014), 1065–1073.
100. 100 Guarnerio, J., Bezzi, M., Jeong, J.C., et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell 165 (2016), 289–302.
101. 101 Chen, L.L., The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol 17 (2016), 205–211.
102. 102 Liu, H., Zhu, L., Liu, B., et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 316 (2012), 196–203.
103. 103 Shao, Y., Ye, M., Jiang, X., et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer 120 (2014), 3320–3328.
104. 104 Zhou, X., Yin, C., Dang, Y., et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep, 5, 2015, 11516.
105. 105 Li, Y., Zheng, Q., Bao, C., et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res 25 (2015), 981–984.
106. 106 Clevers, H., Modeling development and disease with organoids. Cell 165 (2016), 1586–1597.
107. 107 Furukawa, T., Kubota, T., Watanabe, M., et al. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer 53 (1993), 608–612.
108. 108 Furukawa, T., Fu, X., Kubota, T., et al. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 53 (1993), 1204–1208.
109. 109 Zhang, L., Yang, J., Cai, J., et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep, 3, 2013, 2992.
110. 110 Zhu, Y., Tian, T., Li, Z., et al. Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Sci Rep, 5, 2015, 8542.
111. 111 Lau, W.M., Teng, E., Chong, H.S., et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 74 (2014), 2630–2641.
112. 112 Gao, H., Korn, J.M., Ferretti, S., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21 (2015), 1318–1325.
113. 113 Park, H., Cho, S.-Y., Kim, H., et al. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci U S A 112 (2015), 12492–12497.
114. 114 Xie, L., Su, X., Zhang, L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19 (2013), 2572–2583.
115. 115 Sanmamed, M.F., Rodriguez, I., Schalper, K.A., et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice. Cancer Res 75 (2015), 3466–3478.
116. 116 Zhang, L., Liu, Y., Wang, X., et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Sci Rep, 5, 2015, 9447.
117. 117 Eirew, P., Steif, A., Khattra, J., et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518 (2015), 422–426.
118. 118 Sato, T., Stange, D.E., Ferrante, M., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141 (2011), 1762–1772.
119. 119 Engevik, A.C., Feng, R., Choi, E., et al. The development of spasmolytic polypeptide/TFF2-expressing metaplasia (SPEM) during gastric repair is absent in the aged stomach. Cell Mol Gastroenterol Hepatol 2 (2016), 605–624.
120. 120 Dedhia, P.H., Bertaux-Skeirik, N., Zavros, Y., et al. Organoid models of human gastrointestinal development and disease. Gastroenterology 150 (2016), 1098–1112.
121. 121 Hill, D.R., Spence, J.R., Gastrointestinal organoids: understanding the molecular basis of the host-microbe interface. Cell Mol Gastroenterol Hepatol 3 (2017), 138–149.
122. 122 Barker, N., Huch, M., Kujala, P., et al. Lgr5+ ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem cell 6 (2010), 25–36.
123. 123 Stange, D.E., Koo, B.-K., Huch, M., et al. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell 155 (2013), 357–368.
124. 124 Bartfeld, S., Bayram, T., van de Wetering, M., et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 148 (2015), 126–136 e6.
125. 125 Schlaermann, P., Toelle, B., Berger, H., et al. A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro. Gut 65 (2016), 202–213.
126. 126 Li, X., Nadauld, L., Ootani, A., et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 20 (2014), 769–777.
127. 127 Nadauld, L.D., Garcia, S., Natsoulis, G., et al. Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol, 15, 2014, 428.
128. 128 van de Wetering, M., Francies, H.E., Francis, J.M., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
129. 129 Kuboki, Y., Yamashita, S., Niwa, T., et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol 27 (2016), 127–133.
130. 130 Shitara, K., Ohtsu, A., Advances in systemic therapy for metastatic or advanced gastric cancer. J Natl Compr Canc Netw 14 (2016), 1313–1320.
131. 131 Becerra, C., Stephenson, J., Jonker, D.J., et al. Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol, 33(suppl; abstr 4069), 2015.
132. 132 Abdelfatah, E., Kerner, Z., Nanda, N., et al. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol 9 (2016), 560–579.
133. 133 Hecht, J.R., Bang, Y.J., Qin, S.K., et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol 34 (2015), 443–451.
134. 134 Satoh, T., Xu, R.H., Chung, H.C., et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol 32 (2014), 2039–2049.
135. 135 Cunningham, D., Tebbutt, N.C., Davidenko, I., et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol, 33, 2015, 4000.
136. 136 Shah, M.A., Bang, Y.-J., Lordick, F., et al. METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol, 33, 2015, 4012.
137. 137 Pectasides, E., Genomic alterations and targeted therapy in gastric and esophageal adenocarcinoma. Clin Ther 38 (2016), 1589–1599.